Analysts Set Expectations for BioCardia FY2026 Earnings

BioCardia, Inc. (NASDAQ:BCDA) – Investment analysts at HC Wainwright lowered their FY2026 EPS estimates for shares of BioCardia in a research note issued on Thursday, March 26th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings of ($0.71) per share for the year, down from their prior forecast of ($0.69). The consensus estimate for BioCardia’s current full-year earnings is ($3.52) per share.

BioCardia (NASDAQ:BCDA) last announced its earnings results on Tuesday, March 24th. The company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.14.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of BioCardia in a research note on Wednesday, January 21st. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $25.00.

BioCardia Stock Up 4.3%

NASDAQ BCDA opened at $1.21 on Monday. The stock’s 50-day moving average price is $1.22 and its 200-day moving average price is $1.32. The company has a market capitalization of $13.24 million, a P/E ratio of -0.94 and a beta of 0.60. BioCardia has a 52 week low of $1.00 and a 52 week high of $3.20.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Geode Capital Management LLC grew its holdings in BioCardia by 70.4% during the 4th quarter. Geode Capital Management LLC now owns 66,003 shares of the company’s stock valued at $83,000 after buying an additional 27,263 shares in the last quarter. DRW Securities LLC bought a new stake in shares of BioCardia in the 4th quarter worth about $72,000. Finally, Cetera Investment Advisers purchased a new stake in BioCardia during the second quarter valued at approximately $40,000. Hedge funds and other institutional investors own 20.57% of the company’s stock.

BioCardia Company Profile

BioCardia, Inc is a clinical-stage biotechnology company dedicated to developing novel cell-based therapies for patients with cardiovascular disease. The company’s core focus lies in advancing regenerative medicine approaches that address both chronic heart failure and acute myocardial infarction. BioCardia leverages proprietary delivery technologies to optimize the targeted administration of therapeutic cells directly into the heart muscle.

The company’s flagship products include the Helix Transendocardial Delivery System and the CardiAMP Cell Therapy System.